Similarly, the combination of trastuzumab plus pertuzumab has demonstrated ORRs that range from 28 to 32% in patients with HER2-amplified CRC that progressed on or after standard treatments in the MyPathway and TRIUMPH studies27,28. Here, ERBB2 is linked to colorectal carcinoma.